These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38580335)

  • 1. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
    Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment.
    Johnson S; Karpova Y; Guo D; Ghatak A; Markov DA; Tulin AV
    BMC Cancer; 2022 May; 22(1):557. PubMed ID: 35585513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    Pillay N; Tighe A; Nelson L; Littler S; Coulson-Gilmer C; Bah N; Golder A; Bakker B; Spierings DCJ; James DI; Smith KM; Jordan AM; Morgan RD; Ogilvie DJ; Foijer F; Jackson DA; Taylor SS
    Cancer Cell; 2019 Mar; 35(3):519-533.e8. PubMed ID: 30889383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Effect of Ubiquitin-Specific Protease 14 and Poly(ADP-Ribose) Glycohydrolase Co-Inhibition in BRCA1-Mutant, Poly(ADP-Ribose) Polymerase Inhibitor-Resistant Triple-Negative Breast Cancer Cells.
    Li P; Zhu X; Qu H; Han Z; Yao X; Wei Y; Li B; Chen H
    Onco Targets Ther; 2024; 17():741-753. PubMed ID: 39258222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
    Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
    Feng X; Koh DW
    Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
    Gravells P; Grant E; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARG Inhibitors and Functional PARG Inhibition Models.
    Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
    Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes.
    Karpova Y; Johnson SJ; Bordet G; Guo D; Ghatak A; Markov DA; Tulin AV
    Biomed Pharmacother; 2022 Sep; 153():113504. PubMed ID: 36076593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    Coulson-Gilmer C; Morgan RD; Nelson L; Barnes BM; Tighe A; Wardenaar R; Spierings DCJ; Schlecht H; Burghel GJ; Foijer F; Desai S; McGrail JC; Taylor SS
    J Exp Clin Cancer Res; 2021 Oct; 40(1):323. PubMed ID: 34656146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered poly(ADP-ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of poly(ADP-ribose) glycohydrolase.
    Gao H; Coyle DL; Meyer-Ficca ML; Meyer RG; Jacobson EL; Wang ZQ; Jacobson MK
    Exp Cell Res; 2007 Mar; 313(5):984-96. PubMed ID: 17276427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential.
    Min W; Wang ZQ
    Front Biosci (Landmark Ed); 2009 Jan; 14(5):1619-26. PubMed ID: 19273151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies.
    Chen SH; Yu X
    Sci Adv; 2019 Apr; 5(4):eaav4340. PubMed ID: 30989114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-throughput screening-compatible homogeneous time-resolved fluorescence assay measuring the glycohydrolase activity of human poly(ADP-ribose) glycohydrolase.
    Stowell AI; James DI; Waddell ID; Bennett N; Truman C; Hardern IM; Ogilvie DJ
    Anal Biochem; 2016 Jun; 503():58-64. PubMed ID: 27036617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells.
    Fathers C; Drayton RM; Solovieva S; Bryant HE
    Cell Cycle; 2012 Mar; 11(5):990-7. PubMed ID: 22333589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells.
    Zhang M; Lai Y; Vasquez JL; James DI; Smith KM; Waddell ID; Ogilvie DJ; Liu Y; Agoulnik IU
    Sci Rep; 2020 Mar; 10(1):3836. PubMed ID: 32123273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
    Steffen JD; Coyle DL; Damodaran K; Beroza P; Jacobson MK
    J Med Chem; 2011 Aug; 54(15):5403-13. PubMed ID: 21692479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents.
    Matanes E; López-Ozuna VM; Octeau D; Baloch T; Racovitan F; Dhillon AK; Kessous R; Raban O; Kogan L; Salvador S; Lau S; Gotlieb WH; Yasmeen A
    Front Oncol; 2021; 11():745981. PubMed ID: 34778062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.